The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

People who receive a mechanical heart valve require lifelong anticoagulant therapy to prevent thrombus (blood clot) formation on the valve. Patients who receive a bioprosthetic (made with human or ...

Edwards Lifesciences (NYSE: EW) today announced eight-year data highlighting positive long-term outcomes with its proprietary ...

A heart valve surgery fixes or replaces one ... lifelong blood-thinning medication is typically necessary to prevent clots. Bioprosthetic valves, however, may not require long-term anticoagulation.

Edwards Lifesciences (EW) announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary ...

CALC is the principal failure mode of BHV fabricated from glutaraldehyde pretreated porcine aortic valves or bovine pericardium. Covalent binding of APD to residual glutaraldehyde in pericardial ...

The Heart Valve Devices Market is valued at USD 12.18 Billion in 2024 and is expected to reach USD 41.88 Billion by 2035 at a ...

Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22 nd at 4:00 PM ET As part of the event, Mr. Berman will provide a corporate overview and discuss ...

For more than 65 years, Edwards has been the leader in heart valve innovations. To create a more durable heart valve, Edwards developed the RESILIA tissue technology more than two decades ago.

Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly ...